{"doi":"10.1016/j.ejca.2020.11.010","title":"Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma","abstract":"OBJECTIVE: Long-term safety of pembrolizumab in melanoma was analyzed in KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006. PATIENTS AND METHODS: Analysis involved patients who received ≥1 pembrolizumab dose. Lead-time bias was addressed via landmark analyses in patients who were progression-free before day 147. RESULTS: Adverse events (AEs) were analyzed for 1567 patients (median follow-up, 42.4 months). Most AEs were mild/moderate; grade 3/4 treatment-related AEs occurred in 17.7% of patients. Two pembrolizumab-related deaths occurred. Any-grade immune-mediated AEs (imAEs) occurred in 23.0%, most commonly hypothyroidism (9.1%), pneumonitis (3.3%), and hyperthyroidism (3.0%); grade 3/4 imAEs occurred in 6.9% of patients. Most imAEs occurred within 16 weeks of treatment. In landmark analysis, patients who did (n = 79) versus did not (n = 384) develop imAEs had similar objective response rates (ORRs) (64.6% versus 63.0%); median time to response (TTR), 5.6 months for both; median duration of response (DOR), 20.0 versus 25.3 months; median progression-free survival (PFS), 17.0 versus 17.7 months; median overall survival (OS), not reached (NR) versus 43 months (p = 0.1104). Patients who did (n = 17) versus did not (n = 62) receive systemic corticosteroids had similar ORRs (70.6% vs. 62.9%) and median TTR (6.4 vs. 5.6 months) but numerically shorter median PFS (9.9 vs. 17.0 months); median DOR, 14.2 months versus NR; median OS, NR for both. CONCLUSIONS: These results enhance the knowledge base for pembrolizumab in advanced melanoma, with no new toxicity signals after lengthy follow-up of a large population. In landmark analyses, pembrolizumab efficacy was similar regardless of imAEs or systemic corticosteroid use. CLINICAL TRIAL REGISTRY: NCT01295827, NCT01704287, NCT01866319.","journal":"European Journal of Cancer","year":2020,"id":54807,"datarank":3.9370762135966375,"base_score":4.61512051684126,"endowment":4.61512051684126,"self_citation_contribution":0.692268077526189,"citation_network_contribution":3.2448081360704486,"self_endowment_contribution":0.692268077526189,"citer_contribution":3.2448081360704486,"corpus_percentile":null,"corpus_rank":null,"citation_count":100,"citer_count":80,"citers_with_citation_signal":64,"citers_with_endowment":64,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.5446,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT01295827","NCT01866319","NCT01704287"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":90459,"name":"Wen-Jen Hwu","orcid":"0000-0003-1674-0751","position":1,"is_corresponding":false},{"id":282233,"name":"Omid Hamid","orcid":"0000-0002-8238-4655","position":2,"is_corresponding":false},{"id":58599,"name":"Antoni Ribas","orcid":"0000-0003-3669-8458","position":3,"is_corresponding":false},{"id":282234,"name":"Jeffrey S. Weber","orcid":"0000-0002-4962-2957","position":4,"is_corresponding":false},{"id":235283,"name":"Adil Daud","orcid":"0000-0002-6617-8421","position":5,"is_corresponding":false},{"id":4541,"name":"F. Stephen Hodi","orcid":"0000-0001-6825-091X","position":6,"is_corresponding":false},{"id":3666,"name":"Jedd D. Wolchok","orcid":"0000-0001-6718-2222","position":7,"is_corresponding":false},{"id":251287,"name":"Tara C. Mitchell","orcid":"0000-0002-8186-7284","position":8,"is_corresponding":false},{"id":13553,"name":"Peter Hersey","orcid":"0000-0002-3064-737X","position":9,"is_corresponding":false},{"id":282235,"name":"Roxana Dronca","orcid":"0000-0002-5345-2268","position":10,"is_corresponding":false},{"id":282236,"name":"Richard W. Joseph","orcid":"0000-0001-6102-4661","position":11,"is_corresponding":false},{"id":282237,"name":"C. Boutros","orcid":"0000-0001-5659-8791","position":12,"is_corresponding":false},{"id":282238,"name":"Le Min","orcid":"0000-0003-4363-1139","position":13,"is_corresponding":false},{"id":13750,"name":"Georgina V. Long","orcid":"0000-0001-8894-3545","position":14,"is_corresponding":false},{"id":282239,"name":"Jacob Schachter","orcid":"0000-0001-8674-6476","position":15,"is_corresponding":false},{"id":258834,"name":"Igor Puzanov","orcid":"0000-0002-9803-3497","position":16,"is_corresponding":false},{"id":68919,"name":"Reinhard Dummer","orcid":"0000-0002-2279-6906","position":17,"is_corresponding":false},{"id":276656,"name":"Jianxin Lin","orcid":null,"position":18,"is_corresponding":false},{"id":282240,"name":"Nageatte Ibrahim","orcid":"0000-0003-0794-949X","position":19,"is_corresponding":false},{"id":282241,"name":"Scott J. Diede","orcid":"0000-0001-5422-549X","position":20,"is_corresponding":false},{"id":68924,"name":"Matteo S. Carlino","orcid":"0000-0002-7861-4104","position":21,"is_corresponding":false},{"id":282242,"name":"Anthony M. Joshua","orcid":"0000-0001-5159-4580","position":22,"is_corresponding":false},{"id":58598,"name":"Caroline Robert","orcid":"0000-0002-9493-0238","position":0,"is_corresponding":true}],"reference_count":24,"raw_metadata":null,"created_at":"2026-07-18T21:04:14.743014Z","pmid":"33360855","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}